Marstacimab study for people with hemophilia A or B
Treatments studied
Part of Blood & lymphatic, Genetic & congenital clinical trials.
This study looks at a medicine called marstacimab for people with hemophilia A or B. If you are already taking marstacimab or have a prescription for it, this study may help us learn more about how well it works.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have been diagnosed with hemophilia A or B by a doctor who specializes in blood disorders.
- You are currently taking marstacimab or have a prescription to start taking it.
- You are 6 years old or older.
- You receive medical care in the United States.
- You (or your parent or guardian) can sign a form saying you agree to be in the study.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This registry study follows people with hemophilia A or B who are taking marstacimab as their regular preventive treatment. It aims to understand how the medicine works in real life and how patients feel during treatment.
This study looks at how a medicine called Marstacimab affects your body's natural anti-clotting protein (TFPI) in people with severe hemophilia A or B who are already taking it. It involves blood tests to see how well the treatment works.
This Phase 3 study looks at how well and how safely marstacimab works over a longer follow-up period. You may join if you already finished a related parent study for hemophilia, and you can keep up with frequent visits and lab tests.
This study tests if switching from emicizumab to a new medicine called marstacimab is safe and effective for people with severe hemophilia A. You must have been on emicizumab for at least 6 months and not have a history of blood clots or heart disease.
This trial tests a study medicine (marstacimab) for children with severe hemophilia A or B, to see if it can help prevent or reduce bleeding episodes. It may be an option for children who do not have certain other health conditions.
This study tests a new medicine called denecimig (Mim8) for adults newly diagnosed with a rare bleeding disorder called acquired hemophilia A. If you have had a bleed that needs treatment, this trial could help you manage your condition.
Hear when a new Hemophilia trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.